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plants and rats [14] [15] [16] [17] [18] [19] , and has also been used to edit the CCR5 locus in hESCs 13 .
We used the locus encoding the pluripotency-associated gene OCT4 (also known as POU5F1)-one of the few genes that has been successfully targeted in hESCs 6 -to compare the efficiency of ZFN-mediated gene targeting in hESCs with that of conventional homologous recombination. We designed four ZFN pairs that recognize unique sequences in the first intron of the OCT4 gene (Fig.  1a, Supplementary Fig. 1 and Supplementary Table 1 ) and generated targeting donor constructs with short homology arms for the three most active ZFNs pairs. Correct targeting of these donor constructs containing a splice acceptor (SA) followed by an enhanced green fluorescent protein (eGFP)-2A-puromycin cassette (2A is a self-cleaving peptide sequence) results in the expression of two proteins-a fusion protein comprising the first 132 amino acids of human OCT4 fused to eGFP (OCT4 EX1-eGFP ) and puromycin N-acetyltransferase-both under the control of the endogenous OCT4 promoter. Southern blot analysis using external probes 3′ and 5′ to the donor homology regions and an internal probe against eGFP revealed that for ZFN pair #1, 40 out of 42 individual cell lines established from puromycin-resistant clones were correctly targeted (efficiency >94%; Fig. 1b and Table 1 ). ZFN pair #2 had a correct targeting frequency of 36-53% ( Table 1) . Of the remaining clones, most were correctly targeted in the OCT4 locus but also carried additional nonhomologous integrations ( Fig.  1b and Table 1 ). ZFN pair #3 had the lowest targeting efficiency and generated only a few puromycin-resistant clones, some of which were correctly targeted. OCT4 EX1-eGFP -targeted cells maintained a pluripotent state, as indicated by the expression of the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60 and SSEA4 (Fig. 1c) and their ability to form cell types originating from all three developmental germ layers in teratoma-formation assays (Fig. 1d) .
We detected expression of the OCT4 EX1-eGFP fusion protein in hESCs by western blotting with antibodies against OCT4 and eGFP (Fig. 1e) . When targeted hESCs were differentiated into fibroblasts, no OCT4 EX1-eGFP protein was detected (Fig. 1e) and the cells regained puromycin sensitivity, demonstrating the validity of the reporter expression. Unexpectedly, clones targeted by ZFN pair #1 showed significantly lower OCT4 EX1-eGFP protein Realizing the full potential of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) requires efficient methods for genetic modification. However, techniques to generate cell type-specific lineage reporters, as well as reliable tools to disrupt, repair or overexpress genes by gene targeting, are inefficient at best and thus are not routinely used. Here we report the highly efficient targeting of three genes in human pluripotent cells using zinc-finger nuclease (ZFN)-mediated genome editing. First, using ZFNs specific for the OCT4 (POU5F1) locus, we generated OCT4-eGFP reporter cells to monitor the pluripotent state of hESCs. Second, we inserted a transgene into the AAVS1 locus to generate a robust drug-inducible overexpression system in hESCs. Finally, we targeted the PITX3 gene, demonstrating that ZFNs can be used to generate reporter cells by targeting non-expressed genes in hESCs and hiPSCs.
Gene targeting by homologous recombination in hESCs has proven difficult, and since the derivation of the first hESCs more than 10 years ago, only a few reports have described successful gene targeting [1] [2] [3] [4] [5] [6] [7] [8] [9] . These studies illustrate the utility of genetically modifying hESCs by gene targeting, but a general approach to manipulate the hESC genome is still lacking. Recently, a technique based on the introduction of DNA double-strand breaks by site-specific ZFNs to facilitate homologous recombination has been used to target endogenous genes in human cells 10, 11 . A ZFN is generated by fusing the FokI nuclease domain to a DNA recognition domain composed of engineered C2H2 zinc-finger motifs that specify the genomic DNA binding site for the chimeric protein (Fig. 1a) . Upon binding of two such fusion proteins at adjacent genomic sites, the nuclease domains dimerize, become active and cut the genomic DNA. When a donor DNA that is homologous to the target on both sides of the double-strand break is provided, the genomic site can be repaired by homology-directed repair, allowing the incorporation of exogenous sequences placed between the homologous regions 12, 13 . This technique, also called 'genome editing', has been applied in systems not easily amenable to genetic modifications, such as zebrafish, Figure 1 Targeting of OCT4 in heSCs using ZFNs. (a) Schematic overview depicting the targeting strategy for the OCT4 locus. Red boxes, probes used for Southern blot analysis; blue boxes, exons of OCT4; arrows, genomic site cut by the respective ZFN pair. Shown above is a schematic of the donor plasmid design. Donor plasmids were created corresponding to the cleavage location of the three ZFN pairs and carried roughly 700-bp regions of homology to the OCT4 sequence. SA-eGFP, splice acceptor-eGFP sequence; 2A, self-cleaving peptide sequence; PURO, puromycin resistance gene; polyA, polyadenylation sequence. Inset at upper left is a cartoon of two ZFNs binding at a specific genomic site (yellow), leading to dimerization of the FokI nuclease domains. 
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construct with isogenic vector arms into the ROSA26 locus 4 by homologous recombination. However, unpredictable position effects or low targeting frequencies have limited the utility of these methods. To develop a highly efficient and robust expression system, we used ZFN technology to target the AAVS1 locus located on chromosome 19, encoding the PPP1R12C gene, which is ubiquitously expressed. This well-characterized locus has been previously shown to allow stable and long-term expression of transgenes in multiple cell types, including hESCs 20 . To target the first intron of PPP1R12C, we used a ZFN pair that generates a double-strand break at its target locus in hESCs ( Supplementary Fig. 1b and Supplementary Table 1 ) and can be used to efficiently insert transgenes into this locus in transformed expression than clones targeted by ZFN pair #2, as indicated by western blot and FACS analysis ( Fig. 1e and Supplementary Fig. 2 ). Additionally, hESCs targeted by ZFN pair #1 tolerated only puromycin concentrations of 0.5 µg/ml, whereas those targeted by ZFN pair #2 could be maintained in up to 2 µg/ml puromycin (data not shown), suggesting that the former had lower expression of puromycin N-acetyltransferase. One possible explanation of this finding is that the integration of the SA-eGFP-2A-puromycin cassette occurred very close to the splice donor of the first coding exon of OCT4 (separated by 102 bp), perhaps impeding splicing efficiency and resulting in reduced OCT4 EX1-eGFP expression. Approaches to expressing transgenes in hESCs include random integration of expression vectors and the insertion of an expression l e T T e R S with efficiencies of 11% for hESCs and 8% for iPSCs, as determined by Southern blot analysis (Fig. 3b,c and Table 1 ). All tested hESC and hiPSC lines targeted in the PITX3 locus maintained a normal karyotype (hESC n = 3, hiPSC n = 3). The PGK-puromycin cassette was subsequently removed by transient expression of Cre recombinase (Fig. 3b) . The relatively high targeting efficiency in hESCs and hiPSCs demonstrates that ZFN-mediated gene targeting is a robust tool for modifying genes not expressed in hECS so as to generate cell type-specific reporter systems. ZFN-mediated gene targeting therefore has the potential to overcome one of the main obstacles in hESC and hiPSC research. A potential limitation of the ZFN targeting approach is off-target DNA breaks induced at related sequences elsewhere in the genome, which may cause unpredictable genotoxic effects. Although our Southern blot analysis using internal and external probes excluded additional integrations and confirmed the clonality of targeted clones, these analyses do not detect ZFN-mediated double-strand breaks and error-prone repair elsewhere in the genome. To examine off-target cleavage, we determined the DNA binding specificity for all ZFNs by SELEX (Supplementary Table 2) , which made it possible to identify the most probable off-target cleavage sites on a genomewide basis (Supplementary Figs. 8a, 9a, 10a and 11a) . Using the Cel-1 assay, we quantified the frequency of nonhomologous end joining (NHEJ)-mediated alterations in up to ten potential off-target sites in clones generated by four different ZFNs used in this study (Table 1b and Supplementary Figs. 8b,c, 9b,c, 10b,c and 11b,c) . In analyzing 46 genomic loci, we detected one NHEJ alteration at one genomic site in one of four PITX3 clones ( Table 1 and Supplementary Fig.  9b-d) ; all the other putative off-target sites for all the ZFNs in all the clones were wild type. Finally, we determined in heterozygously targeted clones the frequency of NHEJ alterations on the allele that did not carry an integrated transgene. This frequency was 1/18 for the PITX3 clones and 1/12 for the OCT4 clones carrying a disruption on the other allele (Table 1b) ; in all other cases, the other allele remained wild type. To ensure that a functional wild-type allele will be present in heterozygously targeted clones, the recognition sequence of the ZFNs can be designed to recognize intron sequences, as was done for the OCT4 and AAVS1 loci. A recent study 22 described the use of ZFNs to disrupt the PIGA gene in hESCs and hiPSCs through the insertion of a drug-resistance marker; this work, together with our data on targeting five distinct loci in three different genes, demonstrates the utility of ZFNs for disrupting genes in human pluripotent stem cells. In addition, we have engineered both the PITX3 locus, which is not expressed in hESCs, and the OCT4 locus to report on cell fate and the AAVS1 locus to be a 'safe harbor' for an inducible transgene, illuminating the range of genotypes that can be generated with ZFNs. We also note that, to ensure the uniqueness of our intended targets within the human genome, we relied on ZFNs containing 4-6 zinc fingers, which recognize composite sites of 24-36 bp.
ZFN-mediated gene targeting requires only relatively short targeting arms (for AAVS1, about 500 bp for each arm), facilitating the generation of targeting constructs to achieve site-specific integration of exogenous genes whose expression can be controlled by constitutively active, inducible or tissue-specific promoters. This is in contrast to targeting of genes such as OCT4 by conventional homologous recombination, which has been shown to result in targeting efficiencies of 20% and 40% when isogenic targeting arms of 7.9 and 12.8 kb, respectively, were used 6 Two constructs with identical short homology arms were used to target the AAVS1 locus: (i) a gene-trap vector for the PPP1R12C promoter containing a SA-2A-puromycin selection cassette and (ii) a puromycin selection cassette driven from the phosphoglycerol kinase (PGK) promoter (Fig. 2a) . As indicated by Southern blot analysis, both vectors generated ~50% puromycin-resistant clones that had correctly targeted insertions on one or both alleles with no additional random integrations (Fig. 2b, Table 1 and Supplementary Fig. 3 ). The ability to target genes with vectors using a selection cassette controlled by an exogenous promoter is important for targeting genes not expressed in hESCs, as demonstrated below for PITX3. All tested AAVS1-targeted hESCs, including homozygous targeted clones, retained a normal karyotype (n = 4) (Supplementary Fig.  4a ) and remained pluripotent as determined by immunofluorescence staining for pluripotency markers (Supplementary Fig. 4b ) and teratoma-formation assays (Supplementary Fig. 4c) . hiPSCs 21 could be targeted with efficiency similar to that for hESCs ( Supplementary  Fig. 5a ,b and Table 1) To develop a transgenic overexpression system, we targeted to the AAVS1 locus a donor plasmid expressing eGFP under the control of the constitutively active CAGGS promoter (Fig. 2c) . HESCs targeted with this construct showed persistent and uniform eGFP expression (Fig. 2d) . To generate an inducible expression system, an AAVS1 donor plasmid containing a minimal cytomegalovirus (CMV) promoter and a tetracycline response element driving the eGFP cDNA (TetO-eGFP) was targeted into the AAVS1 locus in either the same or the opposite orientation as the PPP1R12C gene (Fig.  2e) . ZFN-mediated targeting of BG01 cells with these donor plasmids yielded correctly targeted heterozygous (AAVS1-TetO-eGFP +/− ) and homozygous (AAVS1-TetO-eGFP +/+ ) hESCs (Fig. 2f,g ) with high efficiencies similar to those described above (TetO-FW, 47%; TetO-BW, 40%; Table 1 ). Correctly targeted hESCs were transduced with a lentivirus carrying the M2rtTA reverse transactivator to render the cells doxycycline (DOX) responsive. In agreement with previously reported lentiviral transduction efficiencies of hESCs, approximately 10% of the cells showed eGFP expression after the addition of DOX (Fig. 2f) . To test DOX-inducible eGFP expression, we withdrew DOX from the cultures for varying lengths of time and found that eGFP fluorescence became undetectable 7 d after DOX withdrawal (Supplementary Fig. 6 ). We next established cell lines that showed limited silencing of the M2rtTA viral transgene by single-cell subcloning (Fig. 2f) . FACS analysis of these cell lines, cultured under different DOX concentrations, revealed a dose-dependent relationship between DOX concentration and eGFP expression (Fig. 2h) . These experiments showed that eGFP expression was dependent on DOX addition and on the presence of M2rtTA, indicating tight regulation of the eGFP expression cassette when integrated into the AAVS1 locus. There were no apparent differences between the two orientations of the TetO-eGFP cassette.
Finally, we tested whether ZFNs could be used to modify genes that are not expressed in hESCs and hiPSCs by targeting the first exon of PITX3. PITX3 is a transcription factor expressed in some differentiated cell types, such as dopaminergic neurons, but not in hESCs. To generate a PITX3 reporter, we designed a targeting construct in which the PITX3 open reading frame was joined after amino acid 32 to the gene for eGFP followed by a polyadenylation signal and a loxPflanked PGK-puromycin cassette (Fig. 3a) . Coelectroporation of the donor plasmid with the PITX3 ZFN pair #2 (Supplementary Fig. 7) into hESCs or two hiPSC 21 l e T T e R S eliminating the need to construct isogenic targeting vectors. Although it is possible that not all nonexpressed genes can be targeted by ZFNs, the extraordinary flexibility available in designing zinc-finger binding motifs 23, 24 will likely allow targeting of a substantial fraction of genes. Thus, this approach should be useful in generating genetic tools to study cell fate decisions and cell type-specific reporter systems to improve hESC differentiation protocols.
Note: Supplementary information is available on the Nature Biotechnology website.
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